Clinical Trial Update: Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ipilimumab with or without nivolumab in relapsed/refractory Hodgkin lymphoma has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-03